When separately assessed, NT-proBNP-guided therapy significantly reduced HF-related hospitalization (OR: 0.531; 95% CI: 0.347 to 0.811; comparison p = 0.003; heterogeneity p = 0.032), whereas BNP-guided therapy did not (OR: 0.599; 95% CI: 0.303 to 1.187; comparison p = 0.142; heterogeneity p = 0.045). This evidence concerns the gene NPPB and hydrops fetalis.